LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study

Abroad (travel likely)RecruitingPHASE2

Conditions

Gastric Cancer Stage IV · Peritoneal Metastases From Gastric Cancer · Gastric or Esophagogastric Junction Adenocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Huangpu District, China
Study coordinator · zyyang@shsmu.edu.cn · 13564877661

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis

Gastric Cancer Stage IV · Peritoneal Metastases

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Gastric Cancer Stage IV

Abroad (travel likely)RecruitingPHASE1, PHASE2

Fuzhou, China

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Solid Tumor · Advanced Cancer · Metastatic Cancer

Abroad (travel likely)RecruitingPHASE2

Goodyear, United States · Duarte, United States

Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer

Gastric Cancer · GastroEsophageal Cancer

Abroad (travel likely)RecruitingPHASE2

Shanghai, China · Shanghai, China